Therapeutic Targeting of Signaling Pathways in Abdominal Aortic Aneurysm: From Pathogenesis to Precision Medicine Authors: Imran Ibrahim Shaikh, Shekhar Singh, Yuling Feng, Khawar Ali Shahzad, Jianfeng Wang, Quan Zhou, Shuanghu Wang, Chunlai Zeng, Chuxiao Shao Published: 2025 ABSTRACT AbstractAbdominal aortic aneurysms (AAAs) are life-threatening cardiovascular disorders with limited treatment options, largely due to an incomplete understanding of their molecular and cellular pathogenesis. A comprehensive elucidation of the mechanisms driving AAA initiation, progression, and rupture is critical for developing novel therapeutic interventions. Emerging research has highlighted the central role of inflammatory processes in AAA pathophysiology, including dysregulated extracellular matrix (ECM) remodeling, chronic vascular inflammation, immune cell infiltration, and vascular smooth muscle cell (VSMC) dysfunction. These pathological processes are regulated by complex signaling pathways with divergent roles in AAA progression: while NF-κB, MAPK, STAT, and Notch signaling exacerbate disease pathogenesis, AMPK, PPAR-γ, and Nrf2 pathways exert protective effects. Notably, the PI3K/Akt and TGF-β signaling cascades demonstrate context-dependent dual roles, capable of either promoting or inhibiting AAA development. This comprehensive review synthesizes current knowledge of AAA pathophysiology with emphasis on druggable targets within these signaling networks. We critically evaluate emerging therapeutic strategies including miRNA-based interventions, nanoparticle-mediated drug delivery systems, and stem cell therapies that offer promising approaches for precision modulation of disease-specific pathways. By integrating current mechanistic understanding with therapeutic development, this review aims to provide a framework for designing effective pharmacological strategies that could transform AAA management from surgical intervention to medical prevention, addressing a critical unmet clinical need.Keywords: abdominal aortic aneurysm, extracellular matrix remodeling, inflammation, vascular smooth muscle cell dysfunction, cellular signaling, therapeutic targets Background Abdominal aortic aneurysm (AAA) represents a significant vascular disorder characterized by permanent, localized dilation of the abdominal aorta, typically defined as a diameter exceeding 3.0 cm or measuring 1.5 times the normal adjacent aortic segment1,2 (Figure 1). Anatomically, approximately 80% of AAAs occur inferior to the renal arteries (infrarenal), with remaining cases classified as suprarenal or pararenal based on their relationship to renal vessels.3,4 True aneurysms, the most common form, involve dilation of all three arterial wall layers, while pseudoaneurysms result from arterial injury leading to blood extravasation between wall layers. Morphologically, AAAs typically demonstrate fusiform (circumferential) expansion, though saccular (asymmetric) variants occasionally occur.5 The clinical significance of AAA lies in its propensity for progressive, often asymptomatic expansion until the catastrophic complication of rupture occurs, carrying mortality rates exceeding 80%.6 Overview of abdominal aortic aneurysm (AAA). This figure summarizes the definition, risk factors, progression, diagnosis, and treatment of AAA. It shows how aneurysms develop and may rupture, highlights key risk factors (eg, age, male sex, smoking), and outlines diagnostic tools (ultrasound, CT) and monitoring intervals. Treatment includes surgical options (open repair, EVAR) and medications like statins, antihypertensives, and aspirin for cardiovascular protection. (↑ indicates increase). This figure is generated using https://BioRender.com. Contemporary epidemiological data reveal a substantial decline in AAA prevalence compared to historical estimates, reflecting significant public health achievements in risk factor modification. Recent large-scale screening programs demonstrate that AAA prevalence among 65-year-old men has decreased from 1.32% to 0.69% between 2010 and 2023 in population-based cohorts.7 General population imaging studies using CT angiography report current prevalence rates of 4.0% in men versus 0.7% in women, maintaining the well-established male predominance with approximately 5-6-fold higher disease burden in males.8,9 Meta-analyses of contemporary screening data demonstrate pooled odds ratios of 3.78 (95% CI 2.80–5.10) for male sex as a risk factor for AAA.10 These figures represent a remarkable reduction from the historical 4–8% prevalence range reported in earlier screening programs, primarily attributed to declining smoking rates and enhanced cardiovascular risk management in high-income countries.7,11 Global mortality patterns reflect similar improvements, with age-standardized mortality rates declining from 2.57 to 1.86 per 100,000 between 1992 and 2021 (estimated annual percentage change −1.36%), though absolute deaths have increased due to population aging.12 Significant regional disparities persist, with age-adjusted mortality in US adults aged 65+ declining dramatically from 32.6 to 13.2 per 100,000 between 1999 and 2020, while high-income Asia Pacific regions maintain among the highest age-standardized death rates at 4.38 per 100,000.13,14 These favorable trends contrast with stable or increasing AAA burdens reported in some Eastern European and lower Socio-demographic Index (SDI) regions, highlighting substantial geographic heterogeneity in AAA epidemiology and underscoring ongoing healthcare disparities that require targeted intervention strategies.12,14 The natural history of AAA progression demonstrates substantial heterogeneity that complicates clinical management. Contemporary studies report means expansion rates of 2.16–2.6 mm/year with considerable individual variability.15,16 While baseline diameter independently predicts growth velocity, it explains only minimal interpatient variability (R2 = 0.054), highlighting the limitation of size-based monitoring alone.17 This variability is particularly evident in sex-specific analyses, where size-stratified analyses in women reveal mean annual growth rates of 0.91 mm/year for aneurysms <3.0 cm, 2.34 mm/year for 3.0–3.9 cm, 2.49 mm/year for 4.0–4.9 cm, and 6.16 mm/year for aneurysms ≥5.0 cm, demonstrating accelerating expansion with increasing diameter.18 Imaging characteristics provide crucial prognostic information beyond simple diameter measurements. The presence of intraluminal thrombus (ILT) doubles expansion rates (median 2.0 vs 1.0 mm/year), especially in smaller aneurysms.19 Growth patterns further stratify risk, with “peak growth” trajectories conferring a 5.24-fold higher hazard (95% CI 1.68–16.38) of requiring surgical intervention within one year compared to “edge growth” patterns.20 Contemporary surveillance data reveal that baseline diameter strongly influences intervention timing, with no patients measuring <4.25 cm requiring repair within two years, compared to 26% of those with baseline diameters ≥4.25 cm.21 The limitations of diameter-based risk assessment become particularly evident in rupture prediction. Recent biomechanical studies demonstrate that peak wall stress and rupture index independently predict rupture risk after adjusting for diameter. Among patients who experienced rupture, the median maximum diameter was 56 mm at last imaging, with median time to rupture of 2.13 years (IQR 0.64–4.72), confirming that catastrophic events occur near conventional intervention thresholds.22 Rupture continues to carry devastating consequences, with overall fatality exceeding 80% and 30-day hospital mortality ranging from 16–36% in contemporary series.23,24 These observations collectively underscore the critical need for advanced biomarkers and personalized risk prediction tools that integrate biomechanical parameters, growth patterns, and molecular signatures to improve patient outcomes beyond current diameter-dependent paradigms. The pathophysiology of AAA involves a complex interplay of chronic inflammation, extracellular matrix degradation, vascular smooth muscle cell apoptosis, and oxidative stress.25,26 These processes are orchestrated by intricate signaling networks that remain incompletely understood. Current management remains predominantly reactive, relying on serial monitoring until aneurysms reach intervention thresholds, with surgical or endovascular repair reserved for high-risk cases. This “watchful waiting” approach fails to address the underlying molecular drivers of disease progression and creates substantial physical and psychological burdens for patients.27 This comprehensive review aims to systematically evaluate the molecular pathogenesis of AAA, with particular focus on identifying and characterizing druggable targets within key signaling pathways governing disease progression. We will critically assess the pathological roles of pro-aneurysmal pathways (NF-κB, MAPK, STAT, Notch) versus protective signaling cascades (AMPK, PPAR-γ, Nrf2), and elucidate the context-dependent functions of PI3K/Akt and TGF-β pathways. Furthermore, we will examine emerging therapeutic strategies including miRNA-based interventions and nanoparticle-mediated drug delivery systems for their potential to modulate critical pathological processes. By integrating mechanistic insights with therapeutic development, this review aims to establish a conceptual framework for advancing targeted pharmacotherapies that could transform AAA management from surgical intervention to medical prevention, addressing a crucial unmet need in cardiovascular medicine. Risk Factors Male sex and advanced age remain well-established non-modifiable risk factors for AAA. Contemporary population-based imaging studies demonstrate AAA prevalence of 4.0% in men versus 0.7% in women, representing an approximately 5-6-fold higher burden in males.8,9 Recent screening cohorts report even more pronounced disparities, with multivariable-adjusted odds ratios of 8.04 (95% CI 4.87–13.28) for male sex in ultrasound screening studies.28 Global Burden of Disease analyses indicate that males experience approximately 2.25-fold higher age-standardized death rates from aortic aneurysm compared to females.14 Age substantially stratifies AAA risk, with peak mortality occurring in men aged 70–74 years and disability-adjusted life years peaking in the 65–69 age group.29 While women develop AAAs at significantly lower absolute rates, they experience disproportionately worse outcomes: in large US inpatient cohorts, women comprised 22.8% of AAA admissions but rupture accounted for 18.4% of female admissions versus 12.6% of male admissions.30 Smoking stands as the most potent modifiable risk factor for AAA, profoundly influencing aneurysm formation, progression, and rupture. Large prospective cohorts demonstrate that current smoking confers hazard ratios of 4.32–4.81 for incident AAA compared to never-smokers, with meta-analyses yielding pooled odds ratios of 3.39 (95% CI 2.57–4.48).10,31,32 The association exhibits pronounced anatomic specificity: UK Biobank analyses report hazard ratios of 8.90 for abdominal aortic aneurysms and 10.47 for ruptured aortic aneurysms in current versus never-smokers, while thoracic aneurysms show no clear association. Dose-response relationships are evident, with smoking ≥20 versus <10 cigarettes daily associated with HR 5.67 for aortic aneurysm incidence.31 Pack-year analyses reveal monotonic risk increases: Japanese cohort data show aortic mortality hazard ratios versus never-smokers of 2.39 for <20 pack-years, 3.57 for 20–39 pack-years, and 3.92 for ≥40 pack-years.33 The smoking effect demonstrates marked sex specificity, with women experiencing disproportionately greater relative risk increases; meta-analyses report a pooled women-to-men relative risk ratio of 1.78 (95% CI 1.32–2.38), indicating current smoking confers 78% greater relative increase in AAA risk in women compared to men.32 Additionally, factors associated with AAA development include hypertension,34 atherosclerosis,35 coronary artery disease,36 dyslipidemia,37 cerebrovascular disease,38 obesity,39 and a positive family history.40 Emerging research highlights genetic/epigenetic contributors like microRNAs and lncRNAs.41 Although diabetes mellitus typically promotes atherosclerosis, type 2 diabetes appears to confer protection against AAA formation.42 Comprehensive meta-analyses of population and clinical studies demonstrate that diabetic patients have approximately 50% lower AAA risk compared to non-diabetic individuals.43 Additionally, diabetes is associated with reduced aneurysm expansion rates and markedly decreased rupture risk.44,45 Symptoms Most AAAs typically remain asymptomatic until they rupture, often discovered during routine physical examinations or diagnostic investigations for other health concerns. Patients with unruptured AAAs may occasionally present with vague symptoms, including abdominal discomfort or radiating pain extending to the lumbar region or groin.46 Larger AAAs can compress nearby structures, such as the ureters, inferior vena cava, or duodenum, potentially leading to symptoms, although this is uncommon. Ischemic symptoms in the lower limbs due to acute thrombosis or embolization of peripheral circulation may occur but are infrequent in AAA patients. Clinical examination may detect a pulsatile epigastric mass on deep abdominal palpation, though this finding has limited diagnostic sensitivity for AAA.47 Alarmingly, 50% of AAA cases first present with rupture, typically into the retroperitoneal space. This rupture can cause symptoms such as back pain, with or without abdominal pain, hypotension, lightheadedness, and a pulsatile epigastric mass.48 Diagnosis Imaging is crucial in identifying AAA, monitoring its growth rate, diagnosing rupture, guiding therapeutic decisions, planning treatment, and assessing post-surgical outcomes. Ultrasonography (US) and computed tomography angiography (CTA) are essential for AAA management. Despite advancements in aortic imaging technologies, ultrasonography remains the preferred method for AAA screening and surveillance due to its wide availability, non-invasive nature, cost-effectiveness, and high diagnostic accuracy.49 US, including colour and duplex imaging, is indicated for AAA screening and diagnosis in asymptomatic patients and offers rapid emergency assessment for symptomatic cases. For comprehensive characterization and procedural planning, CTA is the cornerstone modality. It provides high-resolution, three-dimensional visualization of the aneurysm’s morphology, including precise measurements of maximum diameter, proximal and distal extension (neck), and involvement of visceral branches. Furthermore, CTA is indispensable for detecting critical features such as the presence of an intraluminal thrombus, penetrating atherosclerotic ulcers, and dissection flaps. This detailed anatomical information is vital for determining eligibility and planning both endovascular (EVAR) and open surgical repair. Consequently, CTA is the definitive test for confirming rupture and for pre-procedural assessment and post-operative surveillance.50 Magnetic resonance angiography (MRA) serves as an alternative to CTA, offering advantages such as avoiding radiation exposure and needing iodinated contrast agents. However, MRA is comparatively more expensive, less widely available, and has longer imaging times.51 Although not part of routine AAA management, positron emission tomography–computed tomography (PET–CT) molecular imaging offers unique diagnostic value for characterizing inflammatory aneurysms, mycotic AAAs, and infected endovascular grafts.52 Nevertheless, this technique has limitations, including limited spatiotemporal resolution, radiation exposure, high cost, and restricted availability.53 Treatment Pharmacological Treatment Numerous pharmacological approaches have been explored for potential benefits in the treatment of AAA (Table 1). However, to date, no medical therapy has proven sufficiently effective in reducing AAA growth or preventing rupture to be incorporated into treatment guidelines. Antihypertensive drugs such as beta-blockers and angiotensin-converting enzyme (ACE) inhibitors have shown no impact on AAA expansion.54,55 While antibiotics such as doxycycline significantly lowered plasma markers of proteolytic activity, recent studies found no attenuation of AAA expansion.56 Macrolides (roxithromycin, azithromycin) likewise showed no therapeutic benefit in slowing aneurysm progression.57,58 Although observational data suggest statins may reduce AAA growth rates, larger nonrandomized trials failed to confirm this effect.59 Other pharmacologic agents including NSAIDs, mast cell inhibitors, calcium channel blockers, diuretics, and angiotensin II receptor blockers demonstrated preclinical potential but ultimately showed no efficacy in curbing AAA enlargement in clinical studies. Current randomized clinical trials are examining the impact of ticagrelor, a platelet aggregation inhibitor; telmisartan/valsartan, an angiotensin II receptor blocker (ARB); cyclosporine A, an immunosuppressive agent; and eplerenone, an aldosterone antagonist, on the growth rate of small AAAs. However, there is presently no definitive recommendation for pharmacological intervention to mitigate the risk of AAA progression and rupture.60 Table 1Evidence Summary for Pharmacological Therapies in AAA ManagementAgent/ClassMechanism of ActionHighest Evidence Tier & Key FindingStatus of Human Efficacy & Clinical Guidance1Doxycycline56Broad-spectrum matrix metalloproteinase (MMP) inhibitor.RCT - Multiple RCTs show no significant attenuation of AAA expansion despite reducing plasma proteolytic markers.No clinical efficacy demonstrated. Recommended only in the context of clinical trials, not for standard care.2Beta-Blockers54Reduce hemodynamic stress and heart rate.RCT - Multiple RCTs (eg, Propranolol, Atenolol) show no impact on AAA expansion rates.No clinical efficacy demonstrated. Not recommended for the purpose of slowing AAA growth.3ACE Inhibitors/ARBs55Block the renin-angiotensin system; reduce inflammation and proteolysis.Mixed Evidence (RCT vs Observational) - RCTs for ACE inhibitors show no effect.Observational data for some ARBs is conflicting, but definitive RCT evidence is lacking.No conclusive RCT evidence for efficacy. Not recommended for AAA-specific treatment outside of hypertension management.4Statins59Pleiotropic effects including reduced inflammation and protease activity.Observational Human Data - Retrospective studies suggest reduced growth, but larger non-randomized trials and RCT subgroup analyses have failed to confirm a significant effect.No proven efficacy for AAA growth. Recommended for co-morbid cardiovascular disease, but not specifically for AAA.5Macrolides (Roxithromycin, Azithromycin)57,58Immunomodulatory and anti-inflammatory effects.RCT - Clinical trials demonstrated no therapeutic benefit in slowing aneurysm progression.No clinical efficacy demonstrated. Not recommended for AAA treatment.6Mast Cell Inhibitors, NSAIDs60Various anti-inflammatory and immunomodulatory mechanisms.Animal Model - Demonstrated preclinical potential in reducing AAA formation and progression in rodent models.No human efficacy data. Promising animal data has not been translated to successful clinical studies.7Ticagrelor, Telmisartan, Cyclosporine A, Eplerenone60Platelet inhibition, angiotensin blockade, immunosuppression, aldosterone antagonism.Ongoing RCTs - These agents are currently being evaluated in clinical trials for their impact on the growth rate of small AAAs.Evidence is pending. There is currently no recommendation for their use. Represents the current frontier of clinical translation. Evidence Summary for Pharmacological Therapies in AAA Management Surgical Treatment Currently, surgical intervention remains the only definitively proven treatment to prevent abdominal aortic aneurysm (AAA) rupture and associated mortality. The established indications for repair include AAAs reaching 5.5 cm in diameter for male patients or 5.0 cm for female patients, as well as any symptomatic aneurysm regardless of size.61 For cases where the risks of elective surgery outweigh the potential rupture risk, a conservative approach is recommended. This involves regular monitoring with imaging intervals tailored to aneurysm size: every three years for 3.0–3.9 cm AAAs, annually for 4.0–4.9 cm AAAs, and every 3–6 months for aneurysms ≥5.0 cm, with adjustments made for rapid growth (>1 cm/year) or other high-risk features like elevated wall stress.62 For smaller AAAs below the surgical threshold, a strategy of surveillance combined with optimal medical management has been shown to be safer and more effective than early elective repair. This comprehensive conservative approach emphasizes rigorous cardiovascular risk factor control, including mandatory smoking cessation, dietary modifications, and regular physical activity. Such lifestyle interventions have demonstrated greater efficacy in reducing cardiovascular events and improving overall outcomes compared to early surgical intervention, while also being cost-effective. The combination of size-appropriate monitoring and aggressive medical therapy represents the standard of care for small AAAs.63 Currently, two main surgical interventions are employed for AAA repair: open surgical repair (OSR) and endovascular aneurysm repair (EVAR). OSR involves a midline laparotomy with replacement of the aneurysmal aortic segment using either a tube or bifurcated synthetic graft, followed by closure of the aneurysm sac around the prosthesis.64 This approach carries significant perioperative risks, including cardiac (myocardial infarction), pulmonary (pneumonia), and renal (insufficiency) complications.65 Postoperative wound complications, particularly incisional hernias following midline laparotomy, significantly impair patient recovery after AAA repair.66 Potential long-term complications following AAA repair include graft infections, graft limb occlusion, secondary aortoenteric fistulae, and para-anastomotic aneurysm formation.67 In contrast, EVAR offers a minimally invasive alternative involving percutaneous or open femoral artery access for stent-graft deployment under fluoroscopic guidance after precise angiographic measurements.68 While EVAR reduces immediate surgical risks, it introduces unique complications, particularly endoleaks69 and access site issues, especially in patients with challenging iliac anatomy (small, calcified, or tortuous vessels). The choice between these approaches depends on patient anatomy, comorbidities, and surgical expertise. Both surgical interventions are associated with high risk, cost, longer procedural time, severe complications, high mortality rates in unsuccessful procedures, and poor long-term survival.70 Given the elevated mortality rates associated with rupture and post-surgery, there is a pressing need for alternative pharmacological therapies. Pathogenesis of AAA While the precise pathophysiology of AAA remains incompletely understood, emerging evidence highlights four interconnected pathological processes driving disease progression: (1) dysregulated ECM remodeling, (2) chronic vascular inflammation, (3) immune cell infiltration, and (4) VSMC dysfunction (Figure 2). These processes collectively contribute to structural and biomechanical weakening of the aortic wall in response to hemodynamic stress, aging, and other risk factors. Earlier studies established that AAA development involves both molecular alterations (eg, protease activation, cytokine dysregulation) and mechanical degradation (eg, loss of elastin, collagen disruption). To develop targeted therapies, a deeper investigation of the cellular and molecular mechanisms underlying these pathological changes—particularly their role in aortic wall remodeling and rupture risk is critical. Pathological hallmarks of abdominal aortic aneurysm. AAA lesions are characterized by infiltration of immune cells, inflammation, oxidative stress, extracellular matrix (ECM) degradation, and loss of vascular smooth muscle cells (VSMCs). This figure is generated using https://BioRender.com. Abbreviations: IL, interleukin; MMP, matrix metalloproteinase; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; MCP-1, monocyte chemoattractant protein-1; NET, neutrophil extracellular traps; IFN-γ, interferon-γ; ROS, reactive oxygen species. Aortic Wall In its normal state, the aorta functions to efficiently transmit pulsatile arterial blood pressure and adapt continually to maintain a consistent diameter in response to changing hemodynamic conditions.71 This functionality is contingent upon the elastic properties and material composition of the aortic wall.72 The structural composition of the aortic wall comprises three distinct layers: the tunica intima, tunica media, and tunica adventitia, encompassing the lumen through which blood flow circulates. Each layer serves a specific function and possesses unique mechanical properties. The innermost layer, the intima, directly interfaces with the blood flow. It serves as a selective barrier formed by endothelial cells, preventing blood product infiltration into the wall and facilitating the delivery of oxygen and nutrients from the blood to the inner wall. The middle layer, referred to as the tunica media, represents the thickest vascular layer, measuring ~2 μm distal to the renal arteries. Bounded internally by a prominent internal elastic lamina and externally by a thinner, age-sensitive external elastic lamina, this middle layer consists of concentric elastic lamellae alternating with vascular SMCs. These structural “lamellar units” provide critical circumferential elasticity, protecting against hemodynamic deformation.73 The media’s extracellular matrix contains sparse fibroblasts within a network of elastin, collagen fibers, proteoglycans, and glycosaminoglycans. The outermost tunica adventitia comprises loose collagen fibers, fibroblasts, neural elements, and vasa vasorum micro vessels, with its collagen framework maintaining structural integrity. ECM The primary component of the blood vessel wall is the ECM, offering structural support to the cells. This dynamic structure is pivotal in governing vascular function, functioning critically under both physiological and pathological circumstances. Maintaining proper ECM function is essential for preserving aortic homeostasis and mechanical properties. The key macromolecules comprising the ECM in large arteries include elastin, collagens, glycoproteins, and proteoglycans, all of which are vital for the function and integrity of the vessel wall. In the middle layer of the aorta, smooth muscle cells are responsible for producing proteins such as elastin and collagen, contributing to the ECM in this part of the aorta. In the adventitia layer, fibroblasts produce collagen, osteopontin, and fibronectin, which are specific to this segment of the aortic wall.74 Elastin and collagens are the most significant fibrillar proteins in the ECM of the aortic wall, influencing the passive mechanical properties of the aorta. Although vascular smooth muscle cells (VSMCs) retain contractile responsiveness to physiological stimuli and can thereby modulate aortic wall dynamics, this functional capacity appears to have minimal physiological significance in the abdominal aorta’s overall mechanical behavior.75 Elastin Elastin, constituting 50% of the dry weight of the aorta, is a hydrophobic and insoluble protein, serving as the predominant protein in the vascular wall. The ELN gene encodes elastin, and its soluble precursor, tropoelastin, is produced and released into the extracellular space. Tropoelastin monomers undergo polymerization to generate insoluble mature elastin, which then forms a highly cross-linked, rubber-like network through the action of lysyl oxidase, resulting in the development of elastin fibers.76 Within the middle layer of the aortic wall, elastin fibers are particularly abundant and are peripherally associated with SMCs and collagen fibers, creating lamellar units. Under low tension, the laminae exhibit a wavy configuration, while increased tension causes them to stretch and straighten. Upon tension reduction, the laminae can revert to their original dimensions. Thus, elastin is the primary protein conferring structure to the vascular wall and contributes to elastic recoil in the aorta.77 Collagen Collagen fibers, the second major structural protein in the aortic wall, constitute approximately 20% of the total protein in the normal aorta. The aortic wall contains various types of collagen, with types I and III being the most abundant, comprising 80–90% of the total collagen. The collagen molecule is composed of three polypeptides twisted together to create a triple helix, and covalent cross-linking between these collagen helices forms large, highly organized fibrillar bundles. Lysyl oxidase (LOX) catalyzes the formation of covalent cross-links between collagen molecules, enabling the assembly of mature collagen fibrils the dominant structural elements of the extracellular matrix.78 Within the aortic adventitia, this cross-linked collagen network confers critical tensile strength, both protecting against elastin overdistension and providing mechanical resistance to wall deformation.79 Collagen, being 100–1000 times stiffer than elastin, serves as the load-bearing component at higher pressures, while under normal blood pressure, the stretchy elastic fibers in the middle aortic wall handle the pressure changes. Consequently, elastin fibers and collagen fibrils together create a robust scaffold for the aorta, offering protection against mechanical damage. ECM Remodeling In the vascular wall, remodeling of the ECM is a physiological process essential for maintaining tissue homeostasis and functionality. However, when ECM remodeling becomes excessive or uncontrolled, it can lead to several life-threatening pathological conditions. Abnormal remodeling of the vessel wall diminishes the strength of the aortic wall, and if the forces acting on the aortic wall surpass its strength, it contributes to the development of AAA or leads to rupture. It has been proposed that the rapid fragmentation of elastin fibers may serve as the triggering event in AAA, initiating wall weakening and ultimately causing AAA expansion.80 Under normal conditions, collagen fibers in the aortic wall remain relaxed. However, as an aneurysm forms and expands, these fibers gradually straighten and align until they approach their maximum stretching capacity. Studies have reported that collagen synthesis increases during the early stages of aneurysm formation, suggesting that collagen turnover is important for vessel wall repair and regeneration and maintaining the strength of the aortic wall and its structural integrity during AAA progression.81 This suggests that increased collagen synthesis might occur as a response to increased wall tension as a consequence of increased elastin degradation together with an expanding aorta. But in later stages of the disease, collagen degradation exceeds its synthesis, and thus increased degradation of collagen fibers might reduce the mechanical strength of the aortic wall, which in turn becomes the responsible factor for AAA rupture. Thus, as the disease advances, the remodeling of the ECM leads to gradual deterioration and weakening of the aortic wall. This process culminates in dilation and eventual rupture when the aortic wall can no longer endure the hemodynamic forces. Several cellular and molecular mechanisms contribute to ECM remodeling in the progression of AAAs. Among these, proteolysis and inflammation play crucial roles. Matrix Metalloproteinases (MMPs) Numerous studies propose that the specific degradation of medial elastin is a key factor leading to the weakening and dilation of the aortic wall in AAAs.82 Various works have concentrated on proteinases exhibiting elastolytic activity, with substantial evidence indicating that elastin degradation in AAA formation and progression is predominantly mediated by matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9.83 Normally, MMPs play diverse roles in biological processes, including tissue remodeling, cell growth, proliferation, migration, angiogenesis, vascularization, apoptosis, tissue repair, wound healing, and immune response.84 All matrix metalloproteinases (MMPs) exhibit similar fundamental structural characteristics, consisting of five key domains: a signal peptide that directs protein secretion, an inhibitory propeptide domain that maintains enzyme latency, a catalytic domain responsible for substrate cleavage, a flexible hinge region, and a hemopexin-like domain that contributes to substrate specificity. MMPs are initially secreted in an inactive form known as pro-MMPs, requiring activation for proteolytic activity. The propeptide domain contains a cysteine residue (Cys73), stabilizing the inactive proenzyme. The catalytic domain features an active Zn2+ site bonded to the cysteine residue. The intact Cys73-Zn2+ bond maintains pro-MMP inactivity by preventing water molecules from reacting with the zinc molecule. MMP activation involves disrupting the bond between the active Zn2+ site and the cysteine residue, known as the “cysteine switch”, a conserved mechanism in the MMP family.85 The elevated activity of these enzymes results in excessive ECM degradation, which contributes to the formation of multiple pathological disease conditions, including the development of AAA.86 So, it is crucial to control the MMPs’ concentrations in order to regulate the correct level of the proteolytic activity of active MMPs, and One regulatory system involves the endogenous family of tissue inhibitors of metalloproteinases (TIMPs).87 Physiologically, MMP activation is tightly regulated by TIMPs. Aneurysmal tissues often exhibit an imbalance between MMP and TIMP activities, as indicated by messenger RNA level studies.88 MMP-9, also known as gelatinase B, plays a significant role in elastin, collagen, laminin, gelatin, and fibrinogen degradation. It has been observed that MMP-9 levels and proteolytic activities are upregulated in AAA aortic tissues compared to healthy aortae,89 and highly correlates with aneurysm size. MMP-9 are highly elevated at the site of aneurysmal rupture, showing AAA rupture is associated with higher levels of MMP-9 in the AAA wall.90 Furthermore, higher plasma levels of MMP-9 are observed in AAA and aortic dissection patients.91 Several population-based studies showed that plasma levels of MMP-9 dropped significantly in patients after AAA surgical repair.92 Moreover, several animal models have been employed to investigate the role of MMP-9 in AAA, and MMP-9-deficient mice exhibit protection against aortic dilation and destruction in experimental aneurysms.93 In human AAA, histological analysis confirmed that macrophages are the primary source for MMP-9 in the aortic wall, and it is reported that MMP-9 colocalizes with infiltrating macrophages present in the AAA wall mainly in the media and media-adventitia junction.94 Similar findings are also reported in animal model studies. MMP-9 deficient mice receiving wildtype bone marrow post-nonlethal irradiation showed marked development of AAA, while the converse experiment in which wildtype mice received MMP-9 deficient marrow did not induce aneurysm formation, suggesting macrophage-derived MMP-9 is crucial for AAA formation.95 Overall, the current opinion regarding MMP-9 is that it is positively related to AAA size, more specifically AAA rupture, and that its causality in AAA is independent of its cellular source and mainly due to inflammatory infiltrate macrophages. MMP-2 is a key protease implicated in the early pathogenesis of abdominal aortic aneurysm, playing a central role in the extracellular matrix (ECM) remodeling that drives aneurysm expansion. Primarily produced by vascular smooth muscle cells (VSMCs), MMP-2 exhibits potent elastolytic and gelatinolytic activity, specifically targeting elastin and type IV collagen in the aortic media. While its overall activity levels are generally lower than the inflammation-associated MMP-9 in established aneurysms, increased MMP-2 activity represents an early pathogenic event that precedes significant inflammatory cell infiltration.96,97 Multiple studies in human tissues and animal models consistently demonstrate that elevated MMP-2 activity correlates with characteristic histopathological features of AAA, including elastin fragmentation, collagen disorganization, and progressive aortic dilation.98,99 This evidence positions MMP-2 as a critical initiator of the proteolytic cascade that weakens the aortic wall and facilitates aneurysm development. Although MMPs play a pivotal role in AAA pathogenesis, broad-spectrum MMP inhibition (eg, with doxycycline) has failed to demonstrate clinically meaningful suppression of aneurysm progression in human trials,100 highlighting the complex interactions and multiple mechanisms involved. Inflammatory and Immune Response Cytokines The pivotal role of inflammation in the initiation and progression of AAAs has long been established. Numerous studies indicate that the upregulation of cytokines and chemokines is associated with AAA development. Several key inflammatory mediators, including interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1), have been identified with elevated levels in both the plasma of AAA patients and AAA tissues.101 Interleukin-1β Interleukin (IL) is recognized as a crucial regulator of inflammation and cellular apoptosis in chronic inflammatory diseases. Studies have demonstrated a significant elevation in IL-1β concentration in tissue samples from AAA compared to healthy aortas.102 Moreover, plasma concentrations of IL-1 in male AAA patients were found to be nearly ten times higher than those in the control group.103 Experiments also revealed a substantial increase in IL-1 secretion in AAA.104 Animal studies, particularly using elastase-induced AAA mouse models, showed significantly higher aortic IL-1 protein levels compared to control mice and both genetic depletion of IL-1 and pharmacological inhibition of the IL-1 receptor successfully prevented elastase-induced AAA formation.105 Similarly, in an Angiotensin II (AngII) induced AAA model, inhibiting IL-1 with an antibody effectively inhibited AAA formation.106 Several other animal studies consistently demonstrated that targeting IL-1 protects against aneurysm development.107 In a model of β-aminopropionitrile (BAPN) induced dissecting AA, elevated IL-1 levels were observed in aortic samples, suggesting a local contribution of IL-1 to AAA formation. This involvement was linked to the activation of MMP-2 and MMP-9 and the degradation of elastin fibers, ultimately compromising the biomechanical properties of the aortic wall.108 Interleukin-6 The pro-inflammatory cytokine IL-6 plays a pivotal role in driving the systemic inflammatory response involved in the pathogenesis of various cardiovascular diseases. Specifically, patients with AAA exhibit a high concentration of IL-6 compared to donor aortas, suggesting a potential significance of this cytokine in aneurysm formation.109 Numerous studies have consistently demonstrated an elevated level of circulating IL-6 in AAA patients, which correlates with the diameter of the aorta.110,111 Additionally, IL-6 production was found to be increased in AAA compared to normal aortas.112 Notably, a study presented evidence associating a single nucleotide polymorphism (SNP) that reduces the function of the IL-6 receptor with a decreased risk of developing AAA, reinforcing a potential causative role for IL-6 in human AAA.113 It has been demonstrated that selectively blocking the IL-6 trans-signaling pathway can prevent AAA progression and aortic rupture.114 Several studies have reported associations between IL-6 and its receptor with the risk of AAA.115 Animal research has also revealed that IL-6 is related to aneurysmal disease.116 Animal research, including studies by Nishihara et al, revealed that inhibition of the IL-6 receptor using a monoclonal antibody reduces the diameter of the aorta in a murine model of CaCl2-induced AAA.117 Tamsulosin was also found to attenuate the formation of AAAs by reducing the production of pro-inflammatory cytokines and promoting the preservation of elastin.118 Tumor Necrosis Factor Tumor necrosis factor (TNF) stands out as a pivotal cytokine in numerous inflammatory responses. Extensive clinical evidence collected from numerous studies indicates an elevation of TNF-α in the plasma and serum of patients with AAAs.119 Systematic reviews emphasize that TNF-α is consistently among the most upregulated cytokines in AAAs.120 Furthermore, the expression of TNF-α and TNF-converting enzyme (TACE) is notably heightened in human AAA tissues, particularly in the media and adventitia, compared to the normal aorta.121 This increase is also observed in both human AAA and mouse CaCl2-induced AAA samples in comparison to the normal aorta and temporal depletion of TACE in mice results in reduced AAAs induced by calcium chloride, accompanied by mitigation of ECM disruption and inflammation in the aortic wall.122 Studies by Xiong et al demonstrate that genetic deficiency or pharmacological inhibition of TNF-α using infliximab attenuates calcium chloride-induced AAAs in mice by reducing MMP-2 and MMP-9 expression, along with decreased macrophage infiltration into the aortic tissue.123 Another study revealed that agents such as tumor necrosis factor binding protein (TNF-BP) effectively prevent post-elastase dilation of the aorta in a rat model of elastase-induced AAA.124 Hence, TNF-α, an inflammatory cytokine that induces the release of proteases, plays a substantial role in breaking down structural proteins in the aortic wall, potentially contributing to the development of AAA. Chemokines Chemokines, a family of small secreted peptide cytokines regulating diverse cell functions, primarily immune-cell recruitment, play crucial roles in various pathological conditions such as inflammation, atherosclerosis, altered hematopoiesis, and cancer. Numerous studies have highlighted the prominence of chemokine (C-C motif) ligand 2 (CCL2), also known as MCP-1, within AAA tissue, demonstrating higher expression in aneurysm tissue compared to controls.125 In a particular study, aortic explants from aneurysmal tissue were found to release MCP-1 to a greater extent than occlusive or normal aortic tissue.126 MCP-1, a C-C chemokine, regulates monocyte recruitment to the site of inflammation through its receptor, C-C chemokine receptor-2 (CCR-2). Studies have demonstrated that genetic deletion of CCR-2 substantially attenuated Ang II–induced lumen dilatation in the ascending aorta.127 Beyond the CC chemokine family, G protein-coupled receptor Chemokine (CXC) chemokines and their receptors, CXCR are equally instrumental. The CXCL12/CXCR4 axis, in particular, has been identified as a significant contributor to AAA pathogenesis.128 CXCL12 (SDF-1) promotes the recruitment of pro-inflammatory cells to the aortic wall, and inhibition of the CXCR4 receptor has been shown to limit experimental AAA formation and progression.129 Similarly, CXCR2, activated by CXC chemokines, serves as a significant receptor for macrophage-mediated inflammatory responses. In animal models, pharmacological inhibition of CXCR2 significantly reduced Ang II–induced AAA formation, evident in reduced collagen deposition, elastin degradation, metal matrix metalloprotease expression, and diminished accumulation of macrophage cells in the aortic wall.130 Collectively, these findings underscore that multiple chemokine pathways including CCL2/CCR2, CXCL12/CXCR4, and the CXCR2 axis are coordinately involved in recruiting inflammatory cells and driving the proteolytic cascade in AAA. This highlights their collective potential as therapeutic targets for suppressing aneurysm development. Immune Cells Macrophages Macrophages represent the predominant immune population in abdominal aortic aneurysm tissues, demonstrating complex temporal and spatial distribution patterns throughout disease progression.131–135 While surgical specimens often show diminished macrophage presence likely reflecting late-stage diseaseanimal models demonstrate crucial early infiltration, particularly in the adventitial-medial junction.134,136–142 The macrophage population in AAA originates from two distinct lineages: tissue-resident macrophages derived from embryonic precursors that maintain local vascular homeostasis, and monocyte-derived macrophages recruited from circulation during inflammatory responses.137,143,144 The traditional classification of macrophages, two distinct phenotypes, M1 (classically activated) and M2 (alternatively activated) macrophages, exhibit divergent functions in regulating inflammatory processes.145–150 Both M1 and M2 macrophages are present in AAA, and their polarization during AAA development determines the progression.151 Maintaining a balance between M1 and M2 is crucial for AAA regulation, as an imbalance in the M1/M2 ratio can promote AAA development.152,153 Recent advances in single-cell transcriptomics have fundamentally transformed our understanding of macrophage heterogeneity, identifying at least five functionally distinct subsets that transcend the conventional M1/M2 classification system.154 These include: (1) Tissue-resident macrophages characterized by expression of Cd200, Pla2g2d, Timd4, Il4i1, and Mif, which help maintain local environmental homeostasis; (2) Tissue-repairing macrophages characterized by high expression of Cd163 and Mrc1 (Cd206), along with extracellular matrix organization genes that facilitate vascular remodeling; (3) Anti-inflammatory macrophages, marked by Arg1, Mmp19, and Fn1, which exhibit immunosuppressive properties and may attempt to limit disease progression; (4) Pro-inflammatory macrophages, display a classical inflammatory phenotype characterized by elevated expression of Ccl5, Stat1, Il1b, and Nlrp3, driving the inflammatory cascade through cytokine production and matrix degradation; and (5) IRF7+ macrophages, representing a unique transitional state identified by co-expression of both M1 (Cd52) and M2 (Cd72 and MS4A4A) markers alongside interferon regulatory factor 7 (IRF7), potentially coordinating immune responses through interferon-related pathways. While the field agrees that macrophage polarization significantly influences AAA progression, substantial controversy exists regarding therapeutic targeting strategies. Some studies suggest promoting M2 polarization may attenuate AAA,153 while others argue that specific macrophage subpopulations—particularly GPNMB+ macrophages localized to areas of elastic degradation represent more promising targets.155 The relative contributions of tissue-resident versus monocyte-derived macrophages also remain debated, with emerging evidence suggesting they may drive distinct aspects of pathogenesis. Furthermore, the functional significance of macrophage phenotypic switching during AAA development remains incompletely understood, particularly regarding whether certain transitional states might be harnessed for therapeutic benefit. Neutrophil Some studies suggest circulating neutrophils may be an important contributor to AAA formation in the early phase.156,157 Neutrophils play a significant role in the progression of AAA through various mechanisms, including the formation of neutrophil extracellular traps (NETs), oxidative stress, and inflammatory responses. NETs are implicated in the pathogenesis of AAA, particularly in the adventitia and intraluminal thrombus. Inhibition of NET formation has been shown to prevent the progression of AAA in certain models, such as those induced by angiotensin II, which resemble human disease with thrombus development.158 NETs contribute to tissue injury and inflammation, promoting AAA progression. Inhibition of NET formation through specific pathways, such as PAD4-dependent mechanisms, has been shown to reduce AAA rupture and progression in experimental models.159 Elevated levels of hydrogen peroxide and myeloperoxidase in neutrophils from AAA patients indicate heightened oxidative activity, which is associated with aneurysm development and progression.160 Neutrophils release leukotriene B4, a major chemotactic factor, from the intraluminal thrombus, which recruits additional neutrophils and perpetuates inflammation within the aneurysm site.161 Neutrophil activation and recruitment are also linked to external factors such as periodontal disease, where bacterial DNA from pathogens like Porphyromonas gingivalis has been found in AAA samples, suggesting a role in neutrophil-driven inflammation and aneurysm growth.162 Targeting neutrophil-mediated inflammation and NET formation presents a potential therapeutic strategy for AAA. Nanotherapies designed to inhibit neutrophilic inflammation have shown promise in reducing AAA progression by attenuating NET formation and associated inflammatory responses.163 The use of noninvasive imaging techniques to monitor neutrophil activity and NET formation in AAA patients could aid in early diagnosis and intervention, potentially improving patient outcomes.164 Moreover, neutrophils are the main source of MMPs in AAA.165 While neutrophils are central to AAA progression, it is important to consider the broader inflammatory milieu and the interplay of various immune cells and mediators. The precise temporal window for neutrophil-targeted interventions and the optimal strategy for selective NET inhibition without impairing host defense remain active investigation areas. T Cells T cells play a crucial role in the progression of AAA through their involvement in the chronic inflammatory response within the aortic wall.166,167 The infiltration of different subsets of T cells contributes to the complex inflammatory environment that leads to aortic wall degradation, matrix remodeling, and eventual aneurysm expansion.168 Mainly CD4+T cells are the most abundant T cells infiltrating AAA and When CD4+T cells are not present; the development of AAA is significantly inhibited.169 Research have indicated that all the CD4+T cells subsets (Th1 cells, Th2 cells, Th17 cells, regulatory T (Treg) cells and T follicular helper (Tfh) cells) are involved in the formation of AAA.170 CD8+ T cells, also known as cytotoxic T cells, can directly kill infected or damaged cells. CD8+ T cells contribute to the inflammatory milieu in AAA by secreting IFN-γ, which enhances the activity of MMPs such as MMP-2 and MMP-9. These enzymes degrade the extracellular matrix, weakening the aortic wall and promoting aneurysm formation.171 The study further demonstrated that experimental depletion of CD8+ T cells correlates with attenuated AAA progression, mediated through reduced smooth muscle cell apoptosis and consequent limitation of vascular wall degeneration. These findings implicate CD8+ T cells as key contributors to SMC loss and aneurysmal pathogenesis. While CD8+ T cells are implicated in promoting SMC apoptosis and AAA progression, other immune cells and pathways also contribute to the disease’s complexity. For instance, Vδ2+ T cells are significantly increased in AAA tissues and are major producers of IL-17A, a pro-inflammatory cytokine that may exacerbate inflammation and tissue damage in AAA.172 This highlights the need for comprehensive strategies that address multiple aspects of the immune response in AAA. The relative importance of specific lymphocyte subsets varies considerably across different experimental models, suggesting context-dependent roles that may reflect the heterogeneous nature of human AAA. Furthermore, the antigenic drivers of adaptive immune responses in AAA remain largely unidentified, representing a critical knowledge gap in our understanding of disease mechanisms. B Cells B cells play a significant role in the progression of AAA through various mechanisms, including the production of specific antibodies and interaction with other immune cells.173 B cells organized in tertiary lymphoid organs (TLOs) within the aortic wall are implicated in AAA progression through the production of IgE antibodies. IgE antibodies produced by TLO B cells activate mast cells (MCs), which are enriched at sites of unhealed hematomas in the aortic wall. This activation leads to the production of IL-4, a cytokine that promotes further IgE class-switching and production by B cells, creating an amplification loop that exacerbates aneurysmal progression.174 Overactivated B cells secrete pathological antibodies, such as anti-beta 2 glycoprotein I (anti-β2GPI) IgG, which contribute to AAA formation, particularly in the context of hyper-homocysteinemia (HHcy). HHcy induces the secretion of these antibodies, which polarize inflammatory macrophages in a TLR4-dependent manner, leading to increased elastin degradation and matrix metalloproteinase (MMP) expression, thereby aggravating AAA progression.175 Studies have shown that targeting the B cell-mediated pathways may help reduce inflammation and tissue degradation, potentially slowing or preventing the progression of AAA.176 While T-cell and B-cell depletion strategies show consistent efficacy across multiple animal models, their translational potential remains uncertain given the risks associated with systemic immunosuppression. Vascular Smooth Muscle Cell VSMCs play a vital role in the structure and function of blood vessels, including the aorta. SMCs exhibit functional plasticity in AAA pathogenesis, contributing to both extracellular matrix maintenance and disease-propagating inflammatory responses. SMC dysfunction, apoptosis (cell death), and phenotypic changes are key processes in the development and expansion of AAA. One of the primary mechanisms underlying AAA formation is the phenotypic switching of VSMCs. In healthy aortic walls, VSMCs primarily exhibit a contractile phenotype, maintaining vascular tone and structural integrity. However, in the context of AAA, these cells undergo a phenotypic switch to a synthetic state. This switch is characterized by decreased expression of contractile markers such as calponin and myosin heavy chain, and increased production of extracellular matrix components, inflammatory cytokines, and proteases.177–179 This transition is influenced by various factors, including cytokines, mechanical forces, oxidative stress, and specific signaling pathways. Increased levels of TNF-α in the aortic wall activate the PERK/eIF2α/ATF4 pathway, leading to VSMC apoptosis and promoting a synthetic phenotype.180 Mechanical stress and oxidative stress are known to influence VSMC behavior, which can trigger changes in their contractile properties and promote a synthetic state. Elevated oxidative stress contributes to VSMC dysfunction, impacting their ability to maintain a contractile phenotype.181 Key regulators include SLC44A2, which, when overexpressed, promotes a contractile phenotype through TGF-β/SMAD signaling, while its silencing leads to a synthetic phenotype, exacerbating AAA susceptibility.182,183 Additionally, CCN2 deficiency in smooth muscle cells triggers reprogramming towards a pro-AAA phenotype, indicating its critical role in maintaining VSMC identity and function.184 The phenotypic landscape of VSMCs in AAA is diverse, with single-cell RNA sequencing revealing multiple phenotypes, including contractile, fibroblast-like, and macrophage-like VSMCs, each contributing differently to aneurysm formation.185 These findings underscore the multifaceted regulation of VSMC phenotypic switching, involving genetic, molecular, and mechanical factors, which collectively contribute to the pathophysiology of AAA. SMC apoptosis is indeed a critical factor in the progression of AAA, contributing to the thinning of the aortic wall and compromising its structural integrity, which increases susceptibility to aneurysm expansion and rupture. The upregulation of phosphodiesterase 4D (PDE4D) in SMCs has been shown to promote apoptosis through the cAMP-PKA-pBad axis, suggesting that PDE4D plays a causative role in AAA development, and its inhibition could be a potential therapeutic strategy.186 Single-cell RNA sequencing has revealed that during AAA progression, there is a proportional decrease in major SMC subpopulations, accompanied by down-regulation of contractile markers and up-regulation of pro-inflammatory genes, highlighting the role of SMCs in AAA pathogenesis.135 Mitochondrial dysfunction and oxidative stress in SMCs are also implicated in AAA, with increased reactive oxygen species production and DNA damage observed in AAA-derived SMCs.187 The loss of cysteine-rich protein 2 (CRP2) in SMCs has been shown to attenuate AAA formation by maintaining ECM homeostasis and reducing apoptosis through the Erk1/2-Col III and MMP2 axis.188 Additionally, the long non-coding RNA SENCR has been identified as a suppressor of AAA formation by inhibiting SMC apoptosis and ECM degradation, suggesting its potential as a therapeutic target.189 Collectively, these studies describe that in AAA, SMCs undergo apoptosis, phenotypic switching, and contribute to ECM degradation, all of which weaken the aorta and promote aneurysm expansion. This underscore the importance of preserving SMC integrity and function to limit AAA progression. Endothelial Cells Endothelial cells maintain vascular homeostasis by regulating blood vessel tone, permeability, and anti-inflammatory, anti-thrombotic surface in aorta. Endothelial dysfunction serves as a critical initiating factor in abdominal aortic aneurysm development, transforming the intimal layer from a protective barrier into a active contributor to disease progression. The dysfunctional endothelium exhibits impaired nitric oxide (NO) bioavailability due to eNOS uncoupling, creating a state of oxidative stress through NADPH oxidase overexpression that promotes vascular inflammation and matrix degradation190 This is accompanied by a shift toward pro-inflammatory activation, characterized by increased expression of adhesion molecules (VCAM-1, ICAM-1) and chemokines (CCL2) that facilitate monocyte/macrophage recruitment into the aortic wall.191 Mechanosensitive pathways play a crucial role, as spatially heterogeneous wall shear stress in the infrarenal aorta induces endothelial damage and inflammatory signaling that correlates with preferential aneurysm formation.192 The activated endothelium also demonstrates a pro-coagulant shift through tissue factor induction and von Willebrand factor release, promoting intraluminal thrombus formation that further alters the local proteolytic environment.193 Additional mechanisms include aberrant angiogenic signaling and endothelial-to-mesenchymal transition (EndMT), which contribute to neovessel formation and inflammation amplification within the aneurysmal wall.194 These endothelial changes collectively drive medial degeneration through increased protease induction (particularly MMP-2 and MMP-9), elastin fragmentation, and vascular smooth muscle cell apoptosis. Emerging preclinical evidence suggests that targeting specific endothelial pathways—including eNOS signaling, Kruppel-like factor 11 (KLF11), C-type natriuretic peptide (CNP), VEGF signaling, and ROS generation—may represent promising therapeutic strategies to mitigate aneurysm progression by restoring endothelial homeostasis.193 Signaling Pathways in AAA Pathogenesis: Mechanisms and Therapeutic Implications Several signaling pathways have been implicated in the development of AAA. As illustrated in Figures 3 and 4, some signaling pathways promote AAA progression when activated, while others exert protective effects. Understanding these distinct pathways has been crucial for developing targeted therapeutic approaches, including specific inhibitors for pathogenic pathways and activators for protective signaling molecules. Pro-Aneurysmal Signaling pathways during abdominal aortic aneurysm formation. (↑ indicates increase and ↓ indicates decrease).This figure is generated using https://BioRender.com. Abbreviations: TNFα, tumor necrosis factor α; TNFR, TNF receptor; PAMP, pathogen-associated molecular pattern; DAMP, damage-associated molecular pattern; TLRs, toll-like receptors; AngII, angiotensin II; GPCRs, G protein-coupled receptors; IL-6, interleukin-6; mIL-6R, membrane interleukin-6 receptor; sIL-6R, soluble interleukin-6 receptor; GP130, glycoprotein 130; JAK3, Janus kinase 3; NF-κb, nuclear factor κB; IκB, inhibitor of NF-κB; P, phosphorylation; MEKK, mitogen-activated protein kinase kinase; JNKs, c-Jun N-terminal kinases; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinases; MEK, MAPK/ERK kinase; STAT3, Signal transducer and activator of transcription3; MMP, matrix metalloproteinase; IL-1β, interleukin-1β; MCP-1, monocyte chemoattractant protein-1; ECM, extracellular matrix; CRP, C reactive protein; DLL, delta like canonical Notch ligand; JAG, jagged; NICD, Notch intracellular domain; IL-12, interleukin-12; AP1, activator protein 1; iNOS, inducible nitric oxide synthase; ROS, reactive oxygen species; KLF4, Kruppel-like factor 4; α-SMA, α‑ smooth muscle actin; SM22α, smooth muscle 22α. Protective Signaling pathways that inhibit abdominal aortic aneurysm progression. (↑ indicates increase and ↓ indicates decrease). This figure is generated using https://BioRender.com. Abbreviations: AMPK, AMP-activated protein kinase; LKB1, Liver kinase B1; TGFβ, transforming growth factor β; AMP, adenosine monophosphate; mTORC1, mammalian target of rapamycin complex 1; TβRI/II, transforming growth factor β receptor 1/2; RTK, receptor tyrosine kinase; Ang-II, angiotensin II; GPCRs, G protein-coupled receptors; PI3K, phosphatidylinositol 3-kinase; P, phosphorylation; FoxO4, Forkhead box protein O 4; VSMC, vascular smooth muscle cell; PPAR-γ, Peroxisome proliferator-activated receptors γ; MMP, matrix metalloproteinase; ECM, extracellular matrix. Nuclear Factor Kappa B (NF-κB) Pathway A prominent player in both acute and chronic inflammatory responses associated with AAA is the nuclear factor-kappa B (NF-κB) signaling pathway. The NF-κB signaling pathway primarily consists of five key protein subunits from the NF-κB/Rel family: RelA (p65), RelB, c-Rel, p50/p105 (NF-κB1), and p52/p100 (NF-κB2). These proteins act as inducible transcription factors that regulate gene expression by binding to specific DNA sequences known as κB elements by forming various homo- and heterodimers. In most cell types, NF-κB complexes are retained in the cytoplasm by a family of inhibitory proteins known as inhibitors of NF-κB (IκBs), mainly IB. Activation of NF-κB typically involves the phosphorylation of IκB by the IκB kinase (IKK) complex, which results in IκB ubiquitination and subsequent degradation. This releases NF-κB and allows it to translocate freely to the nucleus. In the nucleus, NF-κB binds to the κB sequence of various genes, thereby activating their transcription. NF-κB directly regulates numerous cytokines and proteases, such as IL-1β, IL-6, TNF-α, and MMPs. NF-κB also regulates the expression of adhesion molecules and chemokines, which induce the migration of inflammatory cells. Multiple factors can trigger NF-κB signaling in AAA diseases, such as Ang-II, MMP9, ROS and hypertension.195–198 Gene enrichment and positive immunostaining of NF-κB p65 and p50 have been observed in AAA tissues.199 In addition, recent studies have demonstrated that NF-κB inhibits transcription of the elastin and collagen genes, leading to suppression of their synthesis.200 Studies have shown that suppression of NF-κB inhibits the formation and progression of AAA by reducing MMP and inflammatory cytokine expression.201 Ijaz et al demonstrated that genetic ablation of Rela (p65) in mesenchymal cells markedly attenuated Ang-II -induced AAA formation. This NF-κB suppression correlated with diminished IL-6 and IL-1β production and reduced infiltration of inflammatory monocytes, highlighting the pathway’s critical role in AAA pathogenesis.202 Qi et al also found that 17-dimethyl-aminoethylamino-17-demethoxy-geldanamycin (17-DMAG) attenuates Ang-II -induced AAA in mice by blocking p65 nuclear translocation.203 Wang et al showed that 3-hydroxyanthranilic acid (3-HAA) promotes Ang-II -induced AAA formation in mice by upregulating mmp2 via a transcription factor NF-κB.204 Thus, these findings show NF-κB is critical in AAA pathogenesis. MAPK Pathways (ERK, JNK, p38 MAPK) The mitogen-activated protein kinase (MAPK) signaling pathway plays a pivotal role in coordinating cellular responses to diverse extracellular signals. This family comprises three core kinase subgroups: Jun N-terminal kinases (JNK1-3), extracellular signal-regulated kinases (ERK1/2), and p38 isoforms (p38α/β/γ/δ). In AAA pathogenesis, both human and rodent studies demonstrate significant upregulation of total and phosphorylated JNK.205 Pharmacological JNK inhibition attenuates experimental AAA progression,206 with multiple JNK-targeting compounds showing comparable protective effects.207–210 Notably, cigarette smoke/nicotine exacerbates AAA via JNK-mediated MMP2/9 induction in Ang-II models.211 Another member, The ERK cascade involves sequential activation of MAPKKK (Raf), MAPKK (MEK1/2), and MAPK (ERK1/2), ultimately phosphorylating transcriptional regulators (eg, STAT1/3, ELK-1, c-FOS, PPAR-γ). ERK-1/-2 activation, has been shown to play critical roles in the pathogenesis of AAA.212,213 In human AAA tissues, as well as in the elastase perfusion and Ang-II infusion models of AAA, the levels of phospho-MEK-1/2 (pMEK-1/2) and pERK are markedly increased.214,215 Consistent with its pathogenic role, ERK inhibition (via CI1040) reduces MMP activity and aneurysm formation in mice.216 JAK/STAT Pathway Signal transducer and activator of transcription (STAT) regulates the transcription of several genes associated with inflammatory and immune responses. The pathway was investigated by Liao et al, who suggest STAT may also be involved in the process of AAA pathogenesis.217 In another set of experimental studies, pharmacological inhibition of STAT3 reduced the incidence and severity of Ang II–induced AAA formation.218 A key mediator in these pathways is IL-6 signaling. IL-6 activates signaling through two distinct pathways one IL-6 bound to the membrane-bound IL-6 receptor (mIL-6R) and another IL-6 also binds to the soluble IL-6 receptor (sIL-6R) that forms a dimer with the coreceptor glycoprotein-130 (gp-130). This dimerization activates Janus kinase (JAK) and leads to the phosphorylation of STATs, which translocate into the nucleus and regulate the expression of target gene that are involved in immune system development, autoimmunity, acute-phase reactions and chronic inflammation. Elevated IL-6 and downstream STAT3 activation have been consistently documented in both aortic tissue and plasma from AAA patients compared to healthy controls.219 Recent mechanistic studies demonstrate that selective inhibition of IL-6 trans-signaling using sgp130Fc significantly enhances survival in experimental AAA models (Ang-II infusion and elastase+TGF-β neutralization), implicating the IL-6/sIL-6R/gp130 axis as a key driver of aneurysmal pathogenesis.114 Thus, this data shows that these signaling pathways play an important role in AAA formation. PI3K/Akt Signaling Pathway The PI3K/Akt signaling pathway plays a dual role in AAA pathogenesis, with effects critically dependent on cellular context and specific isoforms. This pathway regulates multiple processes central to AAA progression, including vascular smooth muscle cell (VSMC) behavior, inflammatory responses, and extracellular matrix integrity. The pathway’s complexity is exemplified by its cell-specific effects: in inflammatory cells such as neutrophils, PI3Kγ activation promotes neutrophil extracellular trap (NET) formation and enhances inflammatory cytokine production, thereby accelerating AAA development. Accordingly, inhibition of PI3Kγ reduces NET formation and inflammation, ameliorating AAA in experimental models.220 Similarly, in macrophages, PI3K inhibition suppresses AAA progression by reducing inflammatory cell infiltration and ECM degradation.221 Conversely, in vascular smooth muscle cells (VSMC), PI3K/Akt activation promotes cell survival and maintains contractile phenotypes, exerting protective effects against aneurysm progression.222 This protective role is further supported by evidence that Akt2 activation in VSMCs contributes to the beneficial effects observed with rapamycin treatment.220 These opposing cell-type-specific effects underscore the necessity for precisely targeted therapeutic strategies. Future approaches should aim to selectively inhibit pathogenic PI3Kγ signaling in inflammatory cells while preserving or enhancing protective Akt signaling in VSMCs, potentially through cell-specific delivery systems that can achieve this sophisticated modulation. TGF-β Signaling Transforming Growth Factor-Beta (TGF-β) signaling exhibits complex, context-dependent roles in abdominal aortic aneurysm pathogenesis, demonstrating both protective and pathogenic functions.222,223 Elevated TGF-β1 levels detected in human AAA tissue and experimental models suggest its involvement in disease progression, though whether this represents a causative pathogenic factor or a compensatory homeostatic response remains unclear.224,225 Evidence supporting TGF-β’s protective role includes studies demonstrating that localized TGF-β1 overexpression in the aortic wall limits aneurysm expansion in rodent models,226,227 while systemic TGF-β neutralization significantly exacerbates AAA prevalence and severity in angiotensin II–infused mice.228 The cellular specificity of TGF-β signaling critically determines its functional outcomes. Research by Angelov et al229 revealed that systemic but not SMC-specific TGF-β signaling blockade significantly increased AAA prevalence and promoted adventitial expansion with macrophage accumulation, whereas SMC-specific inhibition caused medial thinning without substantial effects on inflammation or adventitial expansion. These findings indicate that TGF-β’s protective effects in AAA are mediated primarily through non-SMC populations, likely including immune cells and adventitial fibroblasts, rather than through direct actions on vascular smooth muscle cells. This cellular compartmentalization of TGF-β signaling underscores the therapeutic challenge in targeting this pathway. Future therapeutic strategies should aim for precise cellular and signaling modulation, potentially through cell-type-specific delivery systems or receptor-subtype-selective approaches that enhance protective ECM-stabilizing effects while avoiding disruption of anti-inflammatory signaling in critical protective cell populations. Notch Signaling The Notch signaling pathway plays a significant role in the development and progression of AAA, a serious vascular condition. The pathway is involved in various cellular processes, including cell fate determination, proliferation, and apoptosis, which are crucial in the pathogenesis of AAA. Recent studies have highlighted the potential of targeting the Notch pathway as a therapeutic strategy for AAA. Notch1 signaling is activated in AAA tissues, as evidenced by increased expression of the Notch intracellular domain (NICD) and its target gene Hes1 in both animal models and human AAA samples. The use of γ-secretase inhibitors like dibenzazepine (DBZ) has shown promise in preventing AAA formation by blocking Notch activation. DBZ effectively reduces the incidence and severity of AAA in animal models by inhibiting inflammatory cell accumulation and reversing Th2 immune responses.230 Inhibition of Notch1-mediated inflammation by intermedin (IMD) has been shown to protect against AAA development. IMD reduces the expression of inflammatory factors and macrophage infiltration, which are critical in AAA pathogenesis.231 Pharmacological inhibition of Notch signaling, specifically using DAPT, has been demonstrated to regress pre-established AAA by reducing inflammation and proteolytic activity in the aortic tissue.232 Notch3 activation is linked to aortic aneurysm development by influencing VSMC differentiation. In marfan syndrome, increased Notch3 activation correlates with a contractile phenotypic change in VSMCs, contributing to aneurysm formation. Inhibition of Notch3 can attenuate aortic enlargement and improve survival, suggesting a role in AAA as well.233 Notch1 haploinsufficiency in VSMCs maintains a contractile phenotype and prevents matrix remodeling, which limits aortic dilation in AAA. This highlights the importance of Notch signaling in maintaining VSMC function and preventing aneurysm progression.234 The Notch pathway is a highly conserved signaling mechanism involved in numerous developmental and pathological processes beyond AAA, such as cancer, hematopoiesis, and tissue regeneration. This complexity underscores the need for further research to refine Notch-targeted therapies for AAA and other conditions. AMPK Signaling AMP-activated protein kinase (AMPK) signaling plays a crucial role in the pathogenesis of AAA. AMPK is a key regulator of cellular energy homeostasis and has been implicated in various cellular processes, including inflammation and angiogenesis, which are critical in AAA development. Activation of AMPK has been shown to have protective effects against AAA progression, suggesting its potential as a therapeutic target. AMPK activation has been found to reduce the incidence and severity of AAA in experimental models. In a study using ApoE -/- mice, the AMPK activator AICAR significantly decreased aneurysm formation and associated mortality.235 In this study, Metformin, a common anti-diabetic drug known to activate AMPK, also demonstrated a retardation of AAA progression, highlighting the therapeutic potential of AMPK activation in AAA management. In endothelial cells, AMPK regulates processes like fatty acid oxidation and nitric oxide production, which are relevant to vascular health and may contribute to its protective role in AAA.236 While AMPK activation shows promise in mitigating AAA progression, it is essential to consider the complexity of AMP signaling networks and their broader physiological roles. Further research is needed to fully elucidate the mechanisms by which AMPK influences AAA and to explore its potential in clinical applications. PPAR-γ Pathway Peroxisome proliferator-activated receptors (PPARs), particularly PPAR-γ, serves as a critical modulator in AAA, with emerging evidence supporting its therapeutic potential. PPAR-γ is involved in maintaining the structural integrity of the aorta by regulating elastogenesis and inflammation, which are critical in AAA development. The research highlights the multifaceted role of PPAR-γ in AAA, focusing on its impact on elastic fiber integrity, inflammation modulation, and potential therapeutic applications. PPAR-γ is crucial for the structural integrity of elastic fibers in the aorta. Reduced expression of PPAR-γ leads to fragmentation of elastic fibers and decreased production of essential components like elastin and fibulin-5, which are vital for maintaining aortic wall integrity.237 PPAR-γ agonists, such as rosiglitazone, have been shown to alter the distribution of inflammatory cytokines during AAA formation, reducing pro-inflammatory cytokines like TNF-α and increasing anti-inflammatory cytokines like IL-10.238 n human studies, PPAR-γ agonists decreased macrophage infiltration and expression of inflammatory markers such as TNF-α and MMP-9 in the aortic wall, suggesting a potential therapeutic role in reducing AAA progression.239 Deletion of PPAR-γ in SMCs promotes AAA development by increasing aortic dilatation and elastin degradation. This suggests that PPAR-γ in SMCs is protective against AAA.240 The broad spectrum of PPAR-γ activation effects, including improved endothelial function and reduced oxidative stress, may offer therapeutic benefits in managing AAA and other cardiovascular conditions.241 Nrf2 Pathways The Nrf2 pathways play significant roles in the pathophysiology of AAA through their involvement in oxidative stress and vascular remodeling. Nrf2, a transcription factor, is crucial for regulating antioxidant responses, while NOX enzymes contribute to ROS production, influencing vascular health. The interplay between these pathways affects the progression of AAA by modulating oxidative stress and inflammation. Nrf2 is a key regulator of antioxidant responses, mitigating oxidative stress by upregulating genes involved in redox homeostasis. In AAA, Nrf2 activation is linked to the protection of VSMCs and the prevention of phenotypic switching, which is crucial for maintaining vascular integrity.242 Nrf2 expression is influenced by hemodynamic shear stress, which affects endothelial cell function. Disturbed hemodynamics can lead to endothelial dysfunction, a precursor to AAA, by altering Nrf2 activity.243 Nrf2 can suppress inflammatory responses by regulating the expression of pro-inflammatory cytokines and enzymes, thereby potentially slowing AAA progression.244 NOX enzymes, particularly NOX1 and NOX4, are major sources of ROS in vascular tissues. These enzymes contribute to oxidative stress, which is a critical factor in AAA development. NOX4 has been shown to activate Nrf2, suggesting a feedback mechanism where increased ROS production by NOX enzymes can trigger antioxidant defenses via Nrf2. This interaction may help balance oxidative stress in AAA.245–247 Signaling Network Integration and Stage-Specific Therapeutic Targeting While the individual roles of NF-κB, MAPK, STAT, Notch, AMPK, PPAR-γ, Nrf2, PI3K/Akt, and TGF-β signaling in AAA pathogenesis have been extensively characterized, their functional crosstalk represents a critical layer of complexity that has received insufficient attention. These pathways form an intricate regulatory network where perturbations in one signaling cascade frequently produce compensatory or opposing effects in others. The inflammatory axes demonstrate particularly robust interconnectivity, with NF-κB and MAPK pathways engaging in bidirectional reinforcement while STAT3 activation amplifies NF-κB-mediated cytokine production, establishing a potent inflammatory positive feedback loop.248 The PI3K/Akt pathway serves as a crucial signaling hub, integrating inputs from multiple pathways and influencing both inflammatory and survival responses through its connections to Notch signaling and inflammatory regulation.231 Protective pathways likewise demonstrate significant interdependence. Pharmacologic AMPK activation decreased NF‑κB and STAT‑3 activation in Ang-II models and reduced inflammatory cell infiltration and MMP activity, identifying AMPK as an anti‑inflammatory brake.235 NRF2 activation increases antioxidant gene expression (eg, GCLM) and suppresses ferroptosis in VSMCs; this attenuates structural degeneration that otherwise would be exacerbated by NF‑κB driven inflammation and ROS.249 PPAR-γ exerts its beneficial effects through cross-inhibition of inflammatory pathways, with PPAR-γ agonists demonstrating potent suppression of both NF-κB and STAT signaling in vascular cells.239 The therapeutic implications of this network crosstalk are substantial and stage-dependent. During AAA initiation, therapeutic strategies should prioritize enhancement of protective signaling through AMPK activators and Nrf2 inducers while implementing early NF-κB and MAPK inhibition to prevent inflammatory cascade establishment. In the progression phase, multi-target approaches become essential to simultaneously inhibit NF-κB/MAPK/STAT inflammatory hubs while selectively modulating PI3K isoforms and implementing PPAR-γ agonists to restore metabolic homeostasis. The pre-rupture phase demands even more sophisticated combination therapies targeting multiple pathways concurrently, including MMP inhibitors coupled with potent antioxidants and selective TGF-β pathway modulators. This stage-specific understanding of signaling network dynamics enables the development of precisely timed therapeutic interventions that account for the evolving dominance of different pathways throughout AAA progression, moving beyond single-pathway targeting toward integrated network modulation strategies. The recognition that pathway dominance shifts throughout AAA progression with protective pathways predominating in early stages and inflammatory pathways dominating later phases—provides a crucial framework for designing stage-appropriate therapeutic interventions. Future therapeutic development should focus on multi-target approaches that simultaneously modulate several interconnected pathways, with timing of intervention becoming as important as target selection. This network perspective and temporal understanding of signaling dynamics will be essential for developing effective therapeutic strategies that can adapt to the evolving pathological landscape of AAA progression. Emerging Therapeutic Platforms: Precision Medicine and Translational Challenges Recent advances in AAA research have yielded significant progress in identifying several promising therapeutic targets within key signaling pathways involved in disease progression. Preclinical studies using various animal models have demonstrated that targeted modulation of these pathways can influence AAA development (Table 2). These findings provide a strong foundation for developing novel pharmacological interventions aimed at halting aneurysm growth and preventing rupture. While, recent research has yielded significant progress in developing precision medicine approaches, primarily focusing on miRNA-based therapies, nanoparticle-mediated delivery systems, and stem cell therapies. While these innovative strategies show promising results in preclinical models, substantial translational barriers must be addressed before clinical implementation. Table 2Therapeutic Targeting of Signaling Pathways in AAASignaling PathwayTarget/ActionInterventionAAA ModelEffect on AAAReferenceNFkBNFκB inhibitionOligodeoxynucleotides (ODNs)Elastase inducedDecreased AAA progressionPreserved elastic fibersReduced MMP-2 and −9Suppressed VCAM-1 and MCP-1Inhibited macrophage infiltration[250,251]NFκB inhibitionApigenin (API)Cacl2 inducedAttenuated AAA progressionPreserved elastic fiberInhibited MMP activationModulated vascular smooth muscle cell contractile phenotypic transition[252]NFκB inhibitionAndrographolide (Andro)Elastase inducedAttenuated AAA growthDecreased infiltration of monocytes/macrophages and T cellsReduced the production of proinflammatory cytokines [CCL2, CXCL10, tumor necrosis factor α, and interferon-γ]Suppressed α4 integrin expression and attenuated the ability of monocytes/macrophages to adhere to activated endothelial cells[253]NFκB inhibitionProtein phosphatase 2A (PP2A) activatorsAngiotensin II–inducedReduced AAA incidence along with the corresponding pathologies[254]NFκB inhibitionSol TNF inhibitor, XPro1595Elastase induced, Angiotensin II–inducedImproved elastin integrity scoresAttenuated AAA progression[255]MAPKsJNK inhibitionSP600125Angiotensin II–induced, Cacl2 inducedReduction in aneurysmal diameterReduced MMP activity[206,256,257]JNK inhibitionZoledronateAngiotensin II–inducedAttenuated the expansion of the suprarenal aortaReduced elastin degradation in the media layer of the aorta, and significantly diminished vascular inflammation by reduction in vascular cell adhesion molecule expression and macrophage accumulation,Decreased MMP-2[209]JNK inhibitionQuercetinCacl2 inducedDecreased AAA incidence and inhibited the reactive oxygen species generationNitro-tyrosine formation and lipid peroxidation production in the aortic tissue during AAA development.Lower expression of the p47phox subunit of nicotinamide adenine dinucleotide phosphate oxidase and inducible nitric oxide synthase, as well as coordinated downregulation of manganese-superoxide dismutase activities and glutathione peroxidase (GPx)-1 and GPx-3 expression[210]JNK inhibitionRosiglitazone (RGZ)Angiotensin II–inducedInhibited the occurrence of fatal ruptureReduced maximal dilatation of the aortaReducing Ang II–induced expression of E-selectin, tumor necrosis factor-alpha, and interleukin-6[208,258]JNK inhibitionGinsenoside Rb1Angiotensin II–inducedSuppressed Ang II–induced diameter enlargementExtracellular matrix degradationMatrix metalloproteinase (MMP) productionInflammatory cell infiltrationVascular smooth muscle cell (VSMC) dysfunction.[207]ERK inhibitionAlpha-ketoglutarateElastase inducedPrevented aneurysmal dilation, reduced aortic ruptureAttenuating the macrophage infiltrationElastin degradation and collagen fibers remodelingInhibiting oxidative stress and the inflammatory response[259]ERK inhibitionSimvastatinAngiotensin II–inducedReversed Ang-II-stimulated angiogenesis and MMP secretion by human umbilical vein endothelial cells[216]ERK inhibitionCurcuminAngiotensin II–inducedDecreased the occurrence of AAADecreased macrophage infiltration and cytokines (MCP-1, and TNF-α)Increased level of superoxide dismutase (SOD)[260]p38 MAPK inhibitionDaidzeinAngiotensin II–inducedAttenuated incidence of AAA, inhibited cytokines (TNF-α, IL-1β), suppressed COX-2, MMP-2, TIMP-1, TGF-β1, and iNOS expression[261]JAK/STATJAK inhibitionSuppressor of cytokine signalling-1 (SOCS1)Elastase inducedIncidence of AAA reduced, decreased the maximal aortic dilation, preservation of medial VSMC, decreased the accumulation of CD68+ macrophages, Ly6G+ neutrophils, CD3+ T-cells and CD45R+ B-cells in AAA lesions, reduced gene expression of chemokines (Ccl2 and Ccl5) and cytokines (Ifnγ, Tnfα), Lower gene expression of elastolysis enzymes (Mmp2 and Mmp9)[262]STAT3 inhibitionUrsolic acid (UA)Angiotensin II–inducedAlleviated the degradation of elastin fibers and inflammationDecreased the expression of MMP2, MMP9[263]STAT3 inhibitionS3I-201Angiotensin II–inducedDecreased MMP activity and the ratio of M1/M2 macrophages, wall thickness was markedly increased, decreased elastin degradation[218]PI3K/Akt/mTORPI3K, AKT and mTOR inhibitionMetforminAngiotensin II–inducedPreserved the elastin structure of the aortaInhibited the loss of collagenDecreased cell proliferation, apoptosis, migration and autophagy of vascular smooth muscle cells (VSMCs)[264]PI3K inhibitionWortmanninElastase inducedDecreased elastin destruction score and SMC destruction scoreReduced infiltration of inflammatory cells[221]PI3K and Akt inhibitionIPI-549Elastase inducedReduced aortic macrophages, T cells and neo-angiogenesis, CD45+ leukocytes and CD45+ F4/80+ macrophages[265]mTOR inhibitionRapamycinCacl2 inducedDecreased cytokines (TNF-α, IL-6 and IL-1β)Decreased CD68 macrophagesIncreased α-actin and calponin contractile proteinsReduced MMP-2 and MMP-9[266]TGF-βTGF-β1 inhibitionDaxxAngiotensin II–inducedReduced the damage to elastin, up-regulated the expression levels of α-SMA and SM22α[267]Notchγ-secretase inhibitionDAPTAngiotensin II–inducedReduced inflammatory response and elastin fragmentation,Decrease in the proteolytic activityPreserved vascular smooth muscle cells[232,268,269]γ-secretase inhibitionDibenzoazepine (DBZ)Angiotensin II–inducedPrevented AAA formationPrevented accumulation of macrophages and CD4+ T cellsReversal of Th2 immune responses[230]ADAM10 inhibitionIntermedinAngiotensin II–induced, Cacl2 inducedReduced inflammatory factors expressionDecreased infiltration of CD68 positive macrophages[231]AMPKAMPK activationAICAR (5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside) and metforminAngiotensin II–inducedReduced the incidence, severity and mortality of aneurysm.Alleviated macrophage infiltration and neovascularity.Alleviated the expression of pro-inflammatory factors.Angiogenic factors and the activity of MMPs.[235]PPAR-γPPAR-γ activationRosiglitazone (RGZ)Angiotensin II–inducedReduce the expression of TNF-α in the late stage and increase the expression level of IL-10[238]Nrf2Nrf2 activationCryptotanshinone (CTS)Angiotensin II–inducedPrevented the activation of NLRP3 and GSDMD-initiated pyroptosis in VSMCs, thereby mitigating VSMC inflammation and maintaining the VSMC contractile phenotype.[270]Nrf2 activationItaconateAngiotensin II–inducedInhibited vascular inflammation[271] Therapeutic Targeting of Signaling Pathways in AAA Decreased AAA progression Decreased AAA progression Preserved elastic fibers Preserved elastic fibers Reduced MMP-2 and −9 Reduced MMP-2 and −9 Suppressed VCAM-1 and MCP-1 Suppressed VCAM-1 and MCP-1 Inhibited macrophage infiltration Inhibited macrophage infiltration Attenuated AAA progression Attenuated AAA progression Preserved elastic fiber Preserved elastic fiber Inhibited MMP activation Inhibited MMP activation Modulated vascular smooth muscle cell contractile phenotypic transition Modulated vascular smooth muscle cell contractile phenotypic transition Attenuated AAA growth Attenuated AAA growth Decreased infiltration of monocytes/macrophages and T cells Decreased infiltration of monocytes/macrophages and T cells Reduced the production of proinflammatory cytokines [CCL2, CXCL10, tumor necrosis factor α, and interferon-γ] Reduced the production of proinflammatory cytokines [CCL2, CXCL10, tumor necrosis factor α, and interferon-γ] Suppressed α4 integrin expression and attenuated the ability of monocytes/macrophages to adhere to activated endothelial cells Suppressed α4 integrin expression and attenuated the ability of monocytes/macrophages to adhere to activated endothelial cells Reduced AAA incidence along with the corresponding pathologies Reduced AAA incidence along with the corresponding pathologies Improved elastin integrity scores Improved elastin integrity scores Attenuated AAA progression Attenuated AAA progression Reduction in aneurysmal diameter Reduction in aneurysmal diameter Reduced MMP activity Reduced MMP activity Attenuated the expansion of the suprarenal aorta Attenuated the expansion of the suprarenal aorta Reduced elastin degradation in the media layer of the aorta, and significantly diminished vascular inflammation by reduction in vascular cell adhesion molecule expression and macrophage accumulation, Reduced elastin degradation in the media layer of the aorta, and significantly diminished vascular inflammation by reduction in vascular cell adhesion molecule expression and macrophage accumulation, Decreased MMP-2 Decreased MMP-2 Decreased AAA incidence and inhibited the reactive oxygen species generation Decreased AAA incidence and inhibited the reactive oxygen species generation Nitro-tyrosine formation and lipid peroxidation production in the aortic tissue during AAA development. Nitro-tyrosine formation and lipid peroxidation production in the aortic tissue during AAA development. Lower expression of the p47phox subunit of nicotinamide adenine dinucleotide phosphate oxidase and inducible nitric oxide synthase, as well as coordinated downregulation of manganese-superoxide dismutase activities and glutathione peroxidase (GPx)-1 and GPx-3 expression Lower expression of the p47phox subunit of nicotinamide adenine dinucleotide phosphate oxidase and inducible nitric oxide synthase, as well as coordinated downregulation of manganese-superoxide dismutase activities and glutathione peroxidase (GPx)-1 and GPx-3 expression Inhibited the occurrence of fatal rupture Inhibited the occurrence of fatal rupture Reduced maximal dilatation of the aorta Reduced maximal dilatation of the aorta Reducing Ang II–induced expression of E-selectin, tumor necrosis factor-alpha, and interleukin-6 Reducing Ang II–induced expression of E-selectin, tumor necrosis factor-alpha, and interleukin-6 Suppressed Ang II–induced diameter enlargement Suppressed Ang II–induced diameter enlargement Extracellular matrix degradation Extracellular matrix degradation Matrix metalloproteinase (MMP) production Matrix metalloproteinase (MMP) production Inflammatory cell infiltration Inflammatory cell infiltration Vascular smooth muscle cell (VSMC) dysfunction. Vascular smooth muscle cell (VSMC) dysfunction. Prevented aneurysmal dilation, reduced aortic rupture Prevented aneurysmal dilation, reduced aortic rupture Attenuating the macrophage infiltration Attenuating the macrophage infiltration Elastin degradation and collagen fibers remodeling Elastin degradation and collagen fibers remodeling Inhibiting oxidative stress and the inflammatory response Inhibiting oxidative stress and the inflammatory response Reversed Ang-II-stimulated angiogenesis and MMP secretion by human umbilical vein endothelial cells Reversed Ang-II-stimulated angiogenesis and MMP secretion by human umbilical vein endothelial cells Decreased the occurrence of AAA Decreased the occurrence of AAA Decreased macrophage infiltration and cytokines (MCP-1, and TNF-α) Decreased macrophage infiltration and cytokines (MCP-1, and TNF-α) Increased level of superoxide dismutase (SOD) Increased level of superoxide dismutase (SOD) Alleviated the degradation of elastin fibers and inflammation Alleviated the degradation of elastin fibers and inflammation Decreased the expression of MMP2, MMP9 Decreased the expression of MMP2, MMP9 Decreased MMP activity and the ratio of M1/M2 macrophages, wall thickness was markedly increased, decreased elastin degradation Decreased MMP activity and the ratio of M1/M2 macrophages, wall thickness was markedly increased, decreased elastin degradation Preserved the elastin structure of the aorta Preserved the elastin structure of the aorta Inhibited the loss of collagen Inhibited the loss of collagen Decreased cell proliferation, apoptosis, migration and autophagy of vascular smooth muscle cells (VSMCs) Decreased cell proliferation, apoptosis, migration and autophagy of vascular smooth muscle cells (VSMCs) Decreased elastin destruction score and SMC destruction score Decreased elastin destruction score and SMC destruction score Reduced infiltration of inflammatory cells Reduced infiltration of inflammatory cells Decreased cytokines (TNF-α, IL-6 and IL-1β) Decreased cytokines (TNF-α, IL-6 and IL-1β) Decreased CD68 macrophages Decreased CD68 macrophages Increased α-actin and calponin contractile proteins Increased α-actin and calponin contractile proteins Reduced MMP-2 and MMP-9 Reduced MMP-2 and MMP-9 Reduced the damage to elastin, up-regulated the expression levels of α-SMA and SM22α Reduced the damage to elastin, up-regulated the expression levels of α-SMA and SM22α Reduced inflammatory response and elastin fragmentation, Reduced inflammatory response and elastin fragmentation, Decrease in the proteolytic activity Decrease in the proteolytic activity Preserved vascular smooth muscle cells Preserved vascular smooth muscle cells Prevented AAA formation Prevented AAA formation Prevented accumulation of macrophages and CD4+ T cells Prevented accumulation of macrophages and CD4+ T cells Reversal of Th2 immune responses Reversal of Th2 immune responses Reduced inflammatory factors expression Reduced inflammatory factors expression Decreased infiltration of CD68 positive macrophages Decreased infiltration of CD68 positive macrophages Reduced the incidence, severity and mortality of aneurysm. Reduced the incidence, severity and mortality of aneurysm. Alleviated macrophage infiltration and neovascularity. Alleviated macrophage infiltration and neovascularity. Alleviated the expression of pro-inflammatory factors. Alleviated the expression of pro-inflammatory factors. Angiogenic factors and the activity of MMPs. Angiogenic factors and the activity of MMPs. miRNA-Based Therapeutics: Promise and Practical Hurdles MicroRNAs (miRNAs) have emerged as a promising focus in AAA research due to their regulatory roles in key pathological processes. These small non-coding RNAs modulate gene expression involved in inflammation, ECM remodeling, and VSMC dysfunction - all critical mechanisms in AAA pathogenesis. Specific miRNAs such as miR-29 and miR-27b-3p are involved in extracellular matrix degradation and inflammatory processes, making them potential targets for therapeutic intervention.272 miR-24 has been identified as a potential biomarker for AAA, with studies showing its differential expression in small and large AAAs compared to controls.273 miR-122-5p is significantly downregulated in AAA patients, suggesting its potential as a diagnostic biomarker.274 miR-193a-5p regulates vascular smooth muscle cell proliferation and migration, with its downregulation linked to AAA progression.275 Single nucleotide polymorphisms (SNPs) in miRNAs, such as miR-145, are associated with AAA susceptibility, indicating a genetic component in miRNA regulation and AAA risk.276 However, therapeutic miRNA applications face considerable challenges related to stability and delivery, as naked oligonucleotides are rapidly degraded by serum nucleases and exhibit poor cellular uptake. Additional concerns include off-target effects from unintended gene regulation due to partial sequence complementarity, immunogenicity triggered by synthetic nucleic acids activating pattern recognition receptors, and the fundamental difficulty of achieving targeted delivery to the aortic wall while minimizing systemic exposure. Nanotechnology Approaches: Engineering Solutions and Limitations Recently, the development of nano-therapies has emerged as a promising strategy for treating various vascular diseases, including AAA. Nano micelles, a type of nanoscale drug delivery system along with other nanoparticle-based therapies, offer novel approaches for targeted drug delivery, enhancing therapeutic efficacy while minimizing systemic side effects. These nanotherapeutics hold great potential for addressing the complex molecular and cellular mechanisms underlying AAA, such as inflammation, ECM degradation, and oxidative stress. Nanoparticles engineered to inhibit neutrophilic inflammation, such as LaCD NP, have shown to alleviate AAA progression by targeting neutrophil-mediated inflammatory responses and reducing NETs formation.163 These nanoparticles release rapamycin in response to reactive oxygen species, effectively reducing AAA expansion by inhibiting calcification, oxidative stress, and apoptosis.277 These nanoparticles demonstrate protective effects against AAA development by inactivating Notch1 signaling, reducing elastin degradation, and decreasing pro-inflammatory cytokines.278 A study demonstrated the use of nanomicelles derived from bioactive conjugates, which effectively inhibit inflammatory cell migration and protect VSMCs from oxidative stress and apoptosis. These nanomicelles, particularly TPTN, accumulate in aneurysmal tissues and normalize the pro-inflammatory microenvironment, significantly delaying AAA expansion in rat models.279 Another approach involves statin-loaded micelles that prevent AAA expansion by reducing macrophage infiltration and matrix metalloproteinase-9 activity, showcasing dose-dependent efficacy in rat models.280 Despite these advances, nanotherapies confront significant translational barriers including biocompatibility and toxicity concerns regarding long-term tissue accumulation and clearance pathways. The manufacturing scalability of complex nanoparticles under Good Manufacturing Practice standards presents substantial engineering challenges, while combination products face complex regulatory pathways and potential cost-effectiveness limitations that may restrict accessibility compared to conventional therapies. Stem Cell Therapy: Emerging Opportunities and Translational Challenges Stem cell therapy has emerged as a promising regenerative approach for abdominal aortic aneurysm, primarily leveraging the potent paracrine and immunomodulatory properties of various stem cell population. Derived from bone marrow (BM-MSCs), adipose tissue (AD-MSCs), or umbilical cord sources, these cells mediate therapeutic effects through multiple mechanisms: secretion of trophic factors promoting vascular smooth muscle cell viability and function; release of extracellular vesicles containing regulatory microRNAs and proteins; modulation of macrophage polarization from pro-inflammatory M1 toward anti-inflammatory M2 phenotypes; and suppression of T-cell and B-cell activation that sustains chronic aortic wall inflammation.281 Additionally, MSCs facilitate tissue repair through stimulation of constructive angiogenesis and production of extracellular matrix components that contribute to aneurysmal wall stabilization. There have been a number of experimental and preclinical studies that indicate their promise as a potential AAA treatment. Hashizume et al demonstrated that BM-MSC administration attenuates angiotensin II–induced aortic aneurysm growth in apolipoprotein E-deficient mice, establishing foundational proof-of-concept for cellular therapy in AAA.282 Moreover, based on the work of Li et al, mesenchymal stem cell (MSC) therapy demonstrates efficacy in abdominal aortic aneurysm by attenuating aortic expansion, preserving elastic fiber integrity, and regulating the local immuno-inflammatory microenvironment.283 Subsequent investigation by Schneider et al revealed that BM-MSCs stabilize established aortic aneurysms more effectively than vascular smooth muscle cells in a rat xenograft model, associated with enhanced extracellular matrix preservation.284 Further studies by Tian et al utilizing adipose-derived mesenchymal stem cells (AD-MSCs) in a rat calcium chloride model documented improved elastin content and reduced matrix metalloproteinase activity, suggesting direct modulation of key pathological processes.285 Consistent with these findings, Zilberman et al demonstrated that stem cell-based intervention effectively attenuated aortic dilatation in a porcine aneurysm model.286 Delivery optimization studies have yielded significant insights, with Blose et al demonstrating that periadventitial AD-MSC delivery via sponge-based systems effectively halts elastase-induced AAA progression while preserving elastic lamellar structure.287 Complementary research by Xie et al revealed that intravenous AD-MSC administration exerts potent anti-inflammatory effects, reducing macrophage infiltration, promoting M2 polarization, and expanding regulatory T-cell populations mechanisms associated with attenuated aneurysm expansion.288 The development of advanced delivery platforms, exemplified by Parvizi et al’s perivascular recombinant collagen peptide scaffolds for adventitial AD-MSC transplantation, demonstrates successful prevention of AAA development and progression in combined elastase/calcium chloride models.289 Several studies have shown that intravenous administration of human umbilical cord-derived mesenchymal stem cells.290,291 Despite these promising findings, stem cell translation faces substantial challenges. Significant heterogeneity in cell sourcing and preparation methods complicates standardization, while the inflammatory, proteolytic microenvironment of AAA compromises engraftment efficiency and cellular survival. Safety concerns regarding potential aberrant differentiation and ectopic tissue formation necessitate careful evaluation, alongside optimization of delivery strategies to maximize therapeutic efficacy. Furthermore, the precise molecular mechanisms underlying MSC-mediated protection remain incompletely elucidated, particularly regarding the relative contributions of paracrine signaling versus direct cellular interactions. Addressing these limitations through rigorous mechanistic investigation, standardized production protocols, and advanced delivery system development will be essential for clinical translation of stem cell-based therapies for abdominal aortic aneurysm. Integrated Perspectives and Future Directions The successful translation of these precision medicine approaches will require integrated strategies that combine miRNA, nanoparticle, and cell-based therapies to address the multifactorial nature of AAA pathogenesis. Future success depends on developing robust biomarker systems for patient stratification, creating advanced tissue-specific delivery modalities, establishing comprehensive long-term safety profiles, and advancing regulatory science frameworks for these complex therapeutic platforms. While precision medicine approaches hold tremendous potential for transforming AAA management, acknowledging and systematically addressing these translational challenges through interdisciplinary collaboration is essential for bridging the gap between preclinical promise and clinical reality. Conclusions AAA remains a formidable clinical challenge characterized by asymptomatic progression and catastrophic complications. Despite diagnostic advances enabling earlier detection, current management strategies remain predominantly reactive, limited to surveillance for small AAAs and surgical intervention for high-risk cases. This paradigm fails to address the fundamental pathophysiology driving aneurysm progression while imposing significant physical and psychological burdens on patients. Our review elucidates the complex molecular mechanisms underlying AAA pathogenesis, particularly highlighting the central roles of dysregulated extracellular matrix remodeling, chronic inflammation, immune dysregulation, and vascular smooth muscle cell dysfunction. The opposing influences of key signaling pathways - with NF-κB, MAPK, and STAT promoting disease progression versus the protective effects of AMPK, PPAR-γ, and Nrf2 - present multiple therapeutic opportunities. Particularly noteworthy are the context-dependent dual roles of PI3K/Akt and TGF-β signaling, which require precise therapeutic modulation. Looking ahead, strategic research priorities must focus on translating mechanistic insights into clinical advances. First, comprehensive biomarker development is crucial integrating circulating miRNAs, proteomic signatures, and imaging-based markers to enable early detection, risk stratification, and treatment monitoring. Second, personalized therapeutic approaches should be prioritized, leveraging multi-omics profiling to identify patient-specific signaling vulnerabilities and guide targeted interventions. Third, rational combination strategies demand systematic investigation, particularly targeting complementary pathways (eg, AMPK activation with NF-κB inhibition) while accounting for temporal variations in pathway dominance across AAA stages. Fourth, advanced delivery platforms require optimization, including cell-specific nanoparticle systems and engineered stem cell therapies to achieve spatial precision while minimizing systemic exposure. The clinical translation of emerging interventions particularly miRNA regulators, nanotherapeutics, and cell-based approaches must address key challenges: standardizing manufacturing protocols, establishing long-term safety profiles, and validating efficacy in relevant disease models. Future success will depend on interdisciplinary collaboration integrating computational modeling of signaling networks with functional validation in sophisticated animal models and human tissue systems. Ultimately, these advances promise to transform AAA management from surgical rescue to precision medicine, enabling mechanism-based therapies that prevent progression and rupture. By focusing on these strategic priorities, the field can move toward personalized therapeutic regimens that significantly improve patient outcomes and quality of life—a fundamental shift from the current watchful-waiting paradigm to active, targeted intervention. Funding Statement The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Post-Doctoral Research Start-Up Fund of Lishui People’s Hospital (2024bsh001 & 2025bsh002). Abbreviations AAA, Abdominal aortic aneurysm; VSMCs, vascular smooth muscle cells; ECM, Extracellular matrix; PAMP, Pathogen-associated molecular pattern; GPCRs, G protein-coupled receptors; TNF- α, Tumor necrosis factor α; DAMP, damage-associated molecular pattern; TLRs, Toll-like receptors; Ang-II, Angiotensin II; GPCRs, G protein-coupled receptors; IL-6, Interleukin-6; mIL-6R, Membrane interleukin-6 receptor; sIL-6R, Soluble interleukin-6 receptor; GP130, Glycoprotein 130; JAK3, Janus kinase 3; NF-κB, nuclear factor κB; IκB, Inhibitor of NF-κB; P, Phosphorylation; MEKK, Mitogen-activated protein kinase kinase; JNKs- c, Jun N-terminal kinases; MAPK, Mitogen-activated protein kinase; ERK, Extracellular signal-regulated kinases; STAT3, Signal transducer and activator of transcription3; MMP, Matrix metalloproteinase; IL-1β, Interleukin-1β; MCP-1, monocyte chemoattractant protein-1; ECM, Extracellular matrix; CRP, C reactive protein. Declaration of Generative AI in Scientific Writing The authors declare that no generative AI was used in scientific writing upon preparation of the article. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References